Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | The evolving treatment landscape of renal cell carcinoma

Neil J. Shah • 17 Feb 2022
GU Cancers 2022
Genitourinary Cancer Kidney Cancer Antibodies Axitinib Cabozantinib Lenvatinib Pembrolizumab

Neil J. Shah, MBBS, Memorial Sloan Kettering Cancer Center, New York City, NY, talks on the rapidly evolving treatment landscape of renal cell carcinoma (RCC), highlighting HIF1-alpha inhibitors as an up and coming mono- and combination therapy. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Neil J. Shah

1:45
Real-world outcomes of mRCC in the current IO & TKI era
Neil J. Shah • 18 Feb 2022
0:48
Will immunotherapy take over the treatment landscape of patients high-risk renal cell carcinoma?
Neil J. Shah • 18 Feb 2022
3:36
Real-world outcomes of IO & TKIs in mRCC
Neil J. Shah • 17 Feb 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals